Efficacy of Acyclovir in Pityriasis rosea
Phase 3
- Conditions
- Pityriasis rosea.Pityriasis rosea
- Registration Number
- IRCT20210823052264N2
- Lead Sponsor
- PNS SHIFA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients presenting with pityriasis rosea within first week of eruption of papulosquamous rash.
Either gender between Age 12-70 years.
Exclusion Criteria
Positive venereal disease research laboratory (VDRL) test.
Females with pregnancy or lactation.
Patients who have taken any other specific treatment for PR in last 01 week.
Patients with any cause of immunosuppression like chronic renal failure, diabetes mellitus, HIV positive and malignancy etc.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Response based on clearance of lesions. Timepoint: Patients in both the groups were evaluated clinically on 7th and 14th day of treatment. Method of measurement: Clinical Response Evaluation.
- Secondary Outcome Measures
Name Time Method